Figure 8.

Immunolabeling for GFP was below the threshold for detection in the lumbar spinal cord derived from either naive wild type mice or CB₂^EGFP mice treated with either paclitaxel or its cremophor-based vehicle. Paclitaxel (4 mg/kg i.p. administered on day 0, 2, 4, and 6) or vehicle was administered on 4 alternate days and mice were perfused and tissue dissected during the maintenance phase of CIPN (day 16). Photomicrograph of transverse section of mouse lumbar spinal cord section in (A) untreated wild type mouse, (B) vehicle-treated CB₂^EGFP mouse, and (C) paclitaxel-treated CB₂^EGFP mouse immunolabeled with anti-GFP revealed by AlexaFluor 594 (red) and stained with DAPI (blue). Scale bar in image = 100 µm. CIPN, chemotherapy-induced peripheral neuropathy; EGFP, enhanced green fluorescent protein; GFP, green fluorescent protein.